Contract manufacturing organisation Scinopharm Taiwan has said it plans to invest around $37.6 million in a new high-potency active pharmaceutical …
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals

